Jafron Biomedical Co

Jafron Biomedical Co Receivables

The Accounts Receivable of Jafron Biomedical Co (300529.SZ) as of Oct 16, 2026 is 53.46 M CNY. In the previous year, Accounts Receivable was 74.85 M CNY — a change of -28.58% (lower).

Receivables

53.46 MCNY

YoY

-28.58%

Last updated:

Accounts Receivable of Jafron Biomedical Co is 2024 53.46 M CNY. Accounts Receivable of Jafron Biomedical Co was 2023 74.85 M CNY. It decreases by -28.58% lower compared to the previous year.

The Jafron Biomedical Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
106.20 M CNY
Jan 1, 2018
127.20 M CNY
Jan 1, 2019
158.30 M CNY
Jan 1, 2020
167.40 M CNY
Jan 1, 2021
269.09 M CNY
Jan 1, 2022
221.73 M CNY
Jan 1, 2023
74.85 M CNY
Jan 1, 2024
53.46 M CNY
The Jafron Biomedical Co Receivables history
YEARReceivablesYoY
53.46 MCNY-28.58%
74.85 MCNY-66.24%
221.73 MCNY-17.60%
269.09 MCNY+60.75%
167.40 MCNY+5.75%
158.30 MCNY+24.45%
127.20 MCNY+19.77%
106.20 MCNY+40.85%
75.40 MCNY+44.72%
52.10 MCNY+41.58%
36.80 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co Ltd is a China-based health care company headquartered in Zhuhai. The company focuses on the research, development, production, and sale of hemoperfusion products. It went public on August 2, 2016, with its stock listed under ticker 300529.SZ and ISIN CNE100002995. Jafron employs 3,003 full-time staff and operates within the health care sector. Its products include disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resin bandages. These products are used in treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. Jafron's products are distributed across more than 3,000 hospitals in all 31 provinces of China. The company's website is https://www.jafron.com/. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Accounts Receivable of Jafron Biomedical Co is 53.46 M CNY in 2024.

Accounts Receivable of Jafron Biomedical Co changed from 74.85 M CNY to 53.46 M CNY, representing a -28.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Jafron Biomedical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Jafron Biomedical Co